To acquire 23andMe’s Personal Genome Service, Total Health and Research Services business lines, and its Biobank and ...

Aims to provide cell therapy R&D with standardized MSC products, optimized culture media, and cryopreservation solutions.

CellProthera will tech transfer to CELLforCURE by SEQENS this year, with plans to produce clinical batches starting in 2026.

The previously announced ASTM D4169-22 and ISTA Package Distribution Testing Service expansions are now fully operational.

Shift Bioscience (Shift), a biotech company using an AI-powered virtual cell to fight age-driven diseases, appointed Lord ...